The dilemma of whether to continue TNFα blocker therapy in an ulcerative colitis patient newly diagnosed with a malignant melanoma and melanoma in situ

Zuzarte, LouiseMirhadi, SaraCarr, RichardTso, Simon2023-12-082023-12-082019-11Zuzarte L, Mirhadi S, Carr RA, Tso S. The dilemma of whether to continue TNFα blocker therapy in an ulcerative colitis patient newly diagnosed with a malignant melanoma and melanoma in situ. BMJ Case Rep. 2019 Nov 14;12(11):e232536. doi: 10.1136/bcr-2019-232536.1757-790X10.1136/bcr-2019-23253631732538http://hdl.handle.net/20.500.14200/3158A case report of an ulcerative colitis patient newly diagnosed with a malignant melanoma and melanoma in situ.enDermatologyOncology. Pathology.The dilemma of whether to continue TNFα blocker therapy in an ulcerative colitis patient newly diagnosed with a malignant melanoma and melanoma in situArticle